Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.732
Abstract: Revefenacin is a novel once‐daily, lung‐selective, long‐acting muscarinic antagonist developed as a nebulized inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease. In a randomized, 4‐way crossover study, healthy subjects received a single… read more here.
Keywords: muscarinic antagonist; long acting; prolong interval; healthy subjects ... See more keywords
Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Respiratory Disease"
DOI: 10.1177/17534666221077561
Abstract: Background: Data for bronchodilator deposition via nebulizers and dry powder inhalers (DPIs) in the respiratory tract of patients with chronic obstructive pulmonary disease (COPD) are limited. We used functional respiratory imaging (FRI) to determine deposition… read more here.
Keywords: tiotropium; deposition; nebulizer; disease ... See more keywords